Pharmaceutical Technology

JUNE 11, 2025

The US Food and Drug Administration (FDA) has placed a clinical hold on several of Gilead’s trials evaluating two HIV treatment candidates, though the rest of the drugmaker’s diverse pipeline remains unaffected. Gilead is considered the leading big pharma in HIV treatments. Shares in Nasdaq-listed Gilead opened 0.3%

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents FDA Communication Hospitals 52

Pharmacy Times

JUNE 16, 2025

Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents. Utilizing colony-stimulating factors (CSFs) decreases the incidence of severe FN.

HIV Treatment and Prevention Agents 73

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization 73

IDStewardship

DECEMBER 11, 2024

In this articlea selection of notable peer-reviewed publications from 2024 are provided. BCPS, BCIDP 2024 has been an interesting year forinfectious disease literature dissemination. As 2024 comes to a close, my friend Dr. RANDOMIZED CONTROLLED TRIALS 1. Article Selection by: Bassam Ghanem, Pharm.D., Gauthier, Pharm.D.,

HIV Treatment and Prevention Agents 363

HIV Treatment and Prevention Agents Labelling Hospitals FDA 363

Hospital Pharmacy Europe

JUNE 19, 2025

Despite longstanding knowledge that TB is both preventable and curable, progress has stalled. Quoting data from the WHO Global TB Report 2024 , he underlined how TB incidence rates, after a brief dip, have plateaued and begun to climb once more. million deaths in 2023. Encouragingly, TB vaccine development has somewhat accelerated.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Vaccines Hospitals 52